Alnylam Pharmaceuticals, Inc. (ALNY)
297.73
+5.57
(+1.91%)
USD |
NASDAQ |
Jun 09, 15:58
Alnylam Pharmaceuticals SG&A Expense (Quarterly) : 322.55M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 150.36M |
| Incyte Corp. | 328.09M |
| BioMarin Pharmaceutical, Inc. | 258.30M |
| BridgeBio Pharma, Inc. | 163.90M |
| Insmed, Inc. | 247.26M |